<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02547532</url>
  </required_header>
  <id_info>
    <org_study_id>Fsalvatoremaugeri</org_study_id>
    <nct_id>NCT02547532</nct_id>
  </id_info>
  <brief_title>Microbioma in Sputa From COPD With Alpha-1 Antitrypsin Deficiency</brief_title>
  <acronym>AATD</acronym>
  <official_title>Microbioma in Sputa From COPD With Alpha-1 Antitrypsin Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Salvatore Maugeri</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IRCCS Policlinico S. Matteo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Grifols Biologicals, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fondazione Salvatore Maugeri</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the context of the increasing evidence of the pathogenetic role of microbiome in COPD, our
      aim is to determine the total and specific bacterial and viral load in sputa from patients
      with COPD due to AATD and to correlate these findings with cellular, biochemical and
      immunological characteristics of sputa. These quantitative data obtained from sputum will be
      analyzed in the context of the clinical and physiological parameters of the patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Actual">April 2018</completion_date>
  <primary_completion_date type="Actual">April 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>composition of microbioma in sputa</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>correlation with clinical and physiological parameters</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>Alpha-1 Antitrypsin Deficiency</condition>
  <arm_group>
    <arm_group_label>usual COPD</arm_group_label>
    <description>Patients meeting the diagnostic criteria for COPD and without AATD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>normal smokers</arm_group_label>
    <description>subjects with a history of smoking, without symptoms, without AATD and with normal lung function</description>
  </arm_group>
  <arm_group>
    <arm_group_label>normal non smokers</arm_group_label>
    <description>subjects without a history of smoking, without symptoms, without AATD and with normal lung function</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AATD not treated</arm_group_label>
    <description>patients with COPD, with AATD and not on augmentation therapy for AATD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AATD treated</arm_group_label>
    <description>patients with COPD, with AATD on augmentation therapy for AATD</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>collection of sputum</intervention_name>
    <arm_group_label>AATD not treated</arm_group_label>
    <arm_group_label>AATD treated</arm_group_label>
    <arm_group_label>normal non smokers</arm_group_label>
    <arm_group_label>normal smokers</arm_group_label>
    <arm_group_label>usual COPD</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Normal volunterrs Patients with COPD without AATD Patients with COPD and with AATD
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of COPD and a clinical stable condition, i.e. at least three months from the
             last AECOPD and/or antibiotic treatment.

        For patients with AATD this condition will be diagnosed by laboratory tests showing low
        levels of AAT and genotyping of AATD-related genes.

        . Exclusion Criteria:

          -  The presence of important co-morbidities (diabetes, systemic or organ infections,
             immunodeficiency, tumors, moderate-severe heart failure) will be considered as
             exclusion criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pantaleo Giannuzzi, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Fondazione Salvatore Maugeri</affiliation>
  </overall_official>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>September 9, 2015</study_first_submitted>
  <study_first_submitted_qc>September 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2015</study_first_posted>
  <last_update_submitted>July 31, 2018</last_update_submitted>
  <last_update_submitted_qc>July 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fondazione Salvatore Maugeri</investigator_affiliation>
    <investigator_full_name>Bruno Balbi</investigator_full_name>
    <investigator_title>Head, Pulmonary Rehabilitation Department</investigator_title>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>alpha-1 antitrypsin deficiency</keyword>
  <keyword>microbioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

